Department of Epidemiology, Key Laboratory of Public Health Safety (Ministry of Education), Fudan University School of Public Health, Shanghai 200032, China.
Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, USA.
Vaccine. 2019 Oct 8;37(43):6566-6572. doi: 10.1016/j.vaccine.2019.07.067. Epub 2019 Jul 26.
A hepatitis E (HepE) vaccine was developed and released in China in 2011. Uptake is currently very limited. The aims of this study were to characterize what public health professionals thought about promoting the HepE vaccine in Shanghai, China, and to develop realistic goals for the HepE vaccine based on this information.
Public health professionals from Shanghai and other jurisdictions of China were contacted to participate in in-depth qualitative interviews between October 2017 and August 2018. Participants were asked about their perception of the HepE vaccine roll-out. Codes were initially based on the structure of the questionnaire. Subsequently, similar ideas were further developed into themes based on what was present in the transcript data.
Thirty-five individuals participated. Major topics of discussion included (1) clarifying the roles and responsibilities of private and public institutions in promoting and marketing the HepE vaccine, (2) identifying what methods of promotion were most efficient, and, (3) endeavoring to formulate a reasonable and realistic goal, if any, for HepE prevention and control in China. Participants emphasized that public sector sources can be trusted sources of information (although the private vaccination company can also be useful in disseminating information) and social media such as WeChat can be good ways to disseminate articles (although netizens may be worried about the spread of fake news). Vaccine promotion is restrained given limited levels of knowledge in the government, hospitals, and public health vaccination centers.
Successful promotion and use of this vaccine in China, even in limited settings (for instance, certain workplaces, or certain groups) could provide additional information on long-term safety and could promote its adoption in other regions of the world where HepE has high morbidity among pregnant women and other populations.
中国于 2011 年开发并推出了戊型肝炎（HepE）疫苗。目前，该疫苗的接种率非常有限。本研究旨在了解上海公共卫生专业人员对推广 HepE 疫苗的看法，并根据这些信息为 HepE 疫苗制定切实可行的目标。
联系了来自上海和中国其他辖区的公共卫生专业人员，于 2017 年 10 月至 2018 年 8 月期间进行深入的定性访谈。要求参与者对 HepE 疫苗的推出发表看法。最初，编码是基于问卷的结构进行的。随后，根据转录数据中的内容，将相似的想法进一步发展为主题。
共有 35 人参与。讨论的主要议题包括：（1）明确私营和公共机构在推广和营销 HepE 疫苗方面的角色和责任；（2）确定哪些推广方法最有效；以及（3）努力制定中国 HepE 预防和控制的合理且现实的目标。参与者强调，公共部门来源是可信赖的信息来源（尽管私营疫苗公司也可以在传播信息方面发挥作用），微信等社交媒体是传播文章的好方法（尽管网民可能担心假新闻的传播）。由于政府、医院和公共卫生接种中心的知识有限，疫苗推广受到限制。
在中国，即使在有限的环境下（例如，某些工作场所或特定人群）成功推广和使用这种疫苗，可以提供关于长期安全性的更多信息，并可以促进其在世界其他地区的采用，这些地区的 HepE 在孕妇和其他人群中发病率较高。
